Tang Capital Management AMLX Position
Exited11-Fund ConvergenceTang Capital Management exited their position in Amylyx Pharmaceuticals, Inc. (AMLX) in Q3 2023, after holding the stock for 3 quarters.
The position was first reported in Q1 2023 and has been tracked across 3 quarterly 13F filings.
AMLX is a convergence signal: 11 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 13.6% of float with 14.7 days to cover, indicating significant bearish positioning against the stock.
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Full company profile →Short Interest
13.6%
14.7 days to cover
Tang Capital Management AMLX Position History
Frequently Asked Questions
Does Tang Capital Management own AMLX?
No. Tang Capital Management exited their position in Amylyx Pharmaceuticals, Inc. (AMLX) in Q3 2023. They previously held the stock for 3 quarters.
How many hedge funds own AMLX?
11 specialist biotech hedge funds currently hold AMLX, including Perceptive Advisors, Boxer Capital, Commodore Capital and 8 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy AMLX?
Tang Capital Management's position in AMLX was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's AMLX position increasing or decreasing?
Tang Capital Management completely exited their AMLX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
AMLXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →